Impact of bodyweight‐based starting doses on the safety and efficacy of lenvatinib in primarily Japanese patients with hepatocellular carcinoma
Sign Up to like & getrecommendations! Published in 2022 at "Hepatology Research"
DOI: 10.1111/hepr.13800
Abstract: The phase III REFLECT study utilized bodyweight‐based lenvatinib dosing in patients with unresectable hepatocellular carcinoma, based on results of the phase II Study 202. This post hoc analysis compared efficacy and safety in patients with… read more here.
Keywords: bodyweight based; hepatocellular carcinoma; safety; efficacy ... See more keywords